{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:34:11Z","timestamp":1774312451669,"version":"3.50.1"},"publisher-location":"New York, NY","reference-count":37,"publisher":"Springer US","isbn-type":[{"value":"9781071607701","type":"print"},{"value":"9781071607718","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-1-0716-0771-8_4","type":"book-chapter","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T07:02:49Z","timestamp":1598857369000},"page":"57-67","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development of Antisense Oligonucleotide Gapmers for the Treatment of Huntington\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Tejal","family":"Aslesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"4_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/978-1-4939-7825-0_23","volume":"1780","author":"RM Lane","year":"2018","unstructured":"Lane RM, Smith A, Baumann T et al (2018) Translating antisense technology into a treatment for Huntington\u2019s disease. Methods Mol Biol 1780:497\u2013523. \nhttps:\/\/doi.org\/10.1007\/978-1-4939-7825-0_23","journal-title":"Methods Mol Biol"},{"key":"4_CR2","doi-asserted-by":"publisher","first-page":"175628641877693","DOI":"10.1177\/1756286418776932","volume":"11","author":"CD Wurster","year":"2018","unstructured":"Wurster CD, Ludolph AC (2018) Antisense oligonucleotides in neurological disorders. Ther Adv Neurol Disord 11:1756286418776932. \nhttps:\/\/doi.org\/10.1177\/1756286418776932","journal-title":"Ther Adv Neurol Disord"},{"key":"4_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/B978-0-444-52014-2.00004-5","volume":"100","author":"JP Vonsattel","year":"2011","unstructured":"Vonsattel JP, Keller C, Cortes Ramirez EP (2011) Huntington\u2019s disease\u2014neuropathology. Handb Clin Neurol 100:83\u2013100. \nhttps:\/\/doi.org\/10.1016\/B978-0-444-52014-2.00004-5","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"4_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.parkreldis.2014.12.013","volume":"21","author":"D Zielonka","year":"2015","unstructured":"Zielonka D, Mielcarek M, Landwehrmeyer GB (2015) Update on Huntington\u2019s disease: advances in care and emerging therapeutic options. Parkinsonism Relat Disord 21(3):169\u2013178. \nhttps:\/\/doi.org\/10.1016\/j.parkreldis.2014.12.013","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"4_CR5","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/mds.26007","volume":"29","author":"EJ Wild","year":"2014","unstructured":"Wild EJ, Tabrizi SJ (2014) Targets for future clinical trials in Huntington\u2019s disease: what\u2019s in the pipeline? Mov Disord 29(11):1434\u20131445. \nhttps:\/\/doi.org\/10.1002\/mds.26007","journal-title":"Mov Disord"},{"issue":"3","key":"4_CR6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00041.2009","volume":"90","author":"C Zuccato","year":"2010","unstructured":"Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease. Physiol Rev 90(3):905\u2013981. \nhttps:\/\/doi.org\/10.1152\/physrev.00041.2009","journal-title":"Physiol Rev"},{"issue":"6","key":"4_CR7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, Stanek LM, Wancewicz EV et al (2012) Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74(6):1031\u20131044. \nhttps:\/\/doi.org\/10.1016\/j.neuron.2012.05.009","journal-title":"Neuron"},{"issue":"5","key":"4_CR8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/mt.2008.50","volume":"16","author":"NR Franich","year":"2008","unstructured":"Franich NR, Fitzsimons HL, Fong DM et al (2008) AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington\u2019s disease. Mol Ther 16(5):947\u2013956. \nhttps:\/\/doi.org\/10.1038\/mt.2008.50","journal-title":"Mol Ther"},{"issue":"16","key":"4_CR9","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper SQ, Staber PD, He X et al (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. Proc Natl Acad Sci U S A 102(16):5820\u20135825. \nhttps:\/\/doi.org\/10.1073\/pnas.0501507102","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"4_CR10","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","volume":"94","author":"KM Schoch","year":"2017","unstructured":"Schoch KM, Miller TM (2017) Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuron 94(6):1056\u20131070. \nhttps:\/\/doi.org\/10.1016\/j.neuron.2017.04.010","journal-title":"Neuron"},{"issue":"4","key":"4_CR11","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","volume":"46","author":"X Shen","year":"2018","unstructured":"Shen X, Corey DR (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46(4):1584\u20131600. \nhttps:\/\/doi.org\/10.1093\/nar\/gkx1239","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"4_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1089\/ard.1991.1.11","volume":"1","author":"JM Dagle","year":"1991","unstructured":"Dagle JM, Weeks DL, Walder JA (1991) Pathways of degradation and mechanism of action of antisense oligonucleotides in Xenopus laevis embryos. Antisense Res Dev 1(1):9","journal-title":"Antisense Res Dev"},{"issue":"14","key":"4_CR13","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","volume":"44","author":"RL Juliano","year":"2016","unstructured":"Juliano RL (2016) The delivery of therapeutic oligonucleotides. Nucleic Acids Res 44(14):6518\u20136548. \nhttps:\/\/doi.org\/10.1093\/nar\/gkw236","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"4_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14(1):9\u201321. \nhttps:\/\/doi.org\/10.1038\/nrneurol.2017.148","journal-title":"Nat Rev Neurol"},{"key":"4_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","volume":"57","author":"CF Bennett","year":"2017","unstructured":"Bennett CF, Baker BF, Pham N et al (2017) Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol 57:81\u2013105. \nhttps:\/\/doi.org\/10.1146\/annurev-pharmtox-010716-104846","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"4_CR16","doi-asserted-by":"publisher","first-page":"E563","DOI":"10.3390\/molecules22040563","volume":"22","author":"V Sardone","year":"2017","unstructured":"Sardone V, Zhou H, Muntoni F et al (2017) Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules 22(4):E563. \nhttps:\/\/doi.org\/10.3390\/molecules22040563","journal-title":"Molecules"},{"issue":"15","key":"4_CR17","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.1021\/ja00718a039","volume":"92","author":"F Eckstein","year":"1970","unstructured":"Eckstein F (1970) Nucleoside phosphorothioates. J Am Chem Soc 92(15):4718\u20134723","journal-title":"J Am Chem Soc"},{"issue":"1","key":"4_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.75.1.285","volume":"75","author":"ML Stephenson","year":"1978","unstructured":"Stephenson ML, Zamecnik PC (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A 75(1):285\u2013288","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"4_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493\u2013506","journal-title":"Cell"},{"issue":"21","key":"4_CR20","doi-asserted-by":"publisher","first-page":"9634","DOI":"10.1093\/nar\/gkt725","volume":"41","author":"ME Ostergaard","year":"2013","unstructured":"Ostergaard ME, Southwell AL, Kordasiewicz H et al (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant huntingtin in the CNS. Nucleic Acids Res 41(21):9634\u20139650. \nhttps:\/\/doi.org\/10.1093\/nar\/gkt725","journal-title":"Nucleic Acids Res"},{"issue":"461","key":"4_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar3959","volume":"10","author":"AL Southwell","year":"2018","unstructured":"Southwell AL, Kordasiewicz HB, Langbehn D et al (2018) Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease. Sci Transl Med 10(461):eaar3959. \nhttps:\/\/doi.org\/10.1126\/scitranslmed.aar3959","journal-title":"Sci Transl Med"},{"issue":"1","key":"4_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","volume":"101","author":"A Yamamoto","year":"2000","unstructured":"Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease. Cell 101(1):57\u201366. \nhttps:\/\/doi.org\/10.1016\/S0092-8674(00)80623-6","journal-title":"Cell"},{"issue":"5","key":"4_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/ejhg.2010.229","volume":"19","author":"SC Warby","year":"2011","unstructured":"Warby SC, Visscher H, Collins JA et al (2011) HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur J Hum Genet 19(5):561\u2013566. \nhttps:\/\/doi.org\/10.1038\/ejhg.2010.229","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"4_CR24","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister EL, Kennington L, Straubhaar J et al (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients. Curr Biol 19(9):774\u2013778. \nhttps:\/\/doi.org\/10.1016\/j.cub.2009.03.030","journal-title":"Curr Biol"},{"issue":"3","key":"4_CR25","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/ejhg.2016.169","volume":"25","author":"C Kay","year":"2017","unstructured":"Kay C, Tirado-Hurtado I, Cornejo-Olivas M et al (2017) The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America. Eur J Hum Genet 25(3):332\u2013340. \nhttps:\/\/doi.org\/10.1038\/ejhg.2016.169","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"4_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","volume":"84","author":"SC Warby","year":"2009","unstructured":"Warby SC, Montpetit A, Hayden AR et al (2009) CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 84(3):351\u2013366. \nhttps:\/\/doi.org\/10.1016\/j.ajhg.2009.02.003","journal-title":"Am J Hum Genet"},{"issue":"11","key":"4_CR27","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/mt.2015.128","volume":"23","author":"C Kay","year":"2015","unstructured":"Kay C, Collins JA, Skotte NH et al (2015) Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in Huntington disease patients of European ancestry. Mol Ther 23(11):1759\u20131771. \nhttps:\/\/doi.org\/10.1038\/mt.2015.128","journal-title":"Mol Ther"},{"issue":"10","key":"4_CR28","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/ejhg.2013.2","volume":"21","author":"FK Baine","year":"2013","unstructured":"Baine FK, Kay C, Ketelaar ME et al (2013) Huntington disease in the south African population occurs on diverse and ethnically distinct genetic haplotypes. Eur J Hum Genet 21(10):1120\u20131127. \nhttps:\/\/doi.org\/10.1038\/ejhg.2013.2","journal-title":"Eur J Hum Genet"},{"key":"4_CR29","unstructured":"Wave Life Sciences. (2016) Wave Life Sciences-Platform. \nhttps:\/\/www.wavelifesciences.com\/science\/platform\/\n\n. Accessed November 8 2019"},{"issue":"9","key":"4_CR30","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nbt.3948","volume":"35","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto N, Butler DCD, Svrzikapa N et al (2017) Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat Biotechnol 35(9):845\u2013851. \nhttps:\/\/doi.org\/10.1038\/nbt.3948","journal-title":"Nat Biotechnol"},{"key":"4_CR31","unstructured":"WAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington\u2019s Disease. (2016). \nhttps:\/\/hdsa.org\/news\/wave-life-sciences-receives-orphan-drug-designation-from-fda-for-its-lead-candidate-designed-to-treat-huntingtons-disease\/\n\n. Accessed November 8 2019"},{"key":"4_CR32","unstructured":"Achey MA (2018) Meet the Compounds: WVE-120101 and WVE-120102. \nhttps:\/\/huntingtonstudygroup.org\/hd-insights\/meet-the-compounds-wve-120101-and-wve-120102\/\n\n. Accessed November 8 2019"},{"issue":"3","key":"4_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3233\/JHD-189003","volume":"7","author":"FB Rodrigues","year":"2018","unstructured":"Rodrigues FB, Wild EJ (2018) Huntington\u2019s disease clinical trials corner: august 2018. J Huntingtons Dis 7(3):279\u2013286. \nhttps:\/\/doi.org\/10.3233\/JHD-189003","journal-title":"J Huntingtons Dis"},{"issue":"24","key":"4_CR34","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB et al (2019) Targeting huntingtin expression in patients with Huntington\u2019s disease. N Engl J Med 380(24):2307\u20132316. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1900907","journal-title":"N Engl J Med"},{"key":"4_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259\u2013293. \nhttps:\/\/doi.org\/10.1146\/annurev.pharmtox.010909.105654","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"4_CR36","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1124\/dmd.106.012401","volume":"35","author":"RZ Yu","year":"2007","unstructured":"Yu RZ, Kim TW, Hong A et al (2007) Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35(3):460\u2013468. \nhttps:\/\/doi.org\/10.1124\/dmd.106.012401","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"4_CR37","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","volume":"37","author":"W Shen","year":"2019","unstructured":"Shen W, De Hoyos CL, Migawa MT et al (2019) Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol 37(6):640\u2013650","journal-title":"Nat Biotechnol"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-0771-8_4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T07:04:31Z","timestamp":1598857471000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-0716-0771-8_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9781071607701","9781071607718"],"references-count":37,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-0771-8_4","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"1 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}